Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors

European Journal of Medicinal Chemistry

Volumn 60, Issue , 2013, Pages 410-420

  Zhang, Zhichao ^a   Liu, Chengwu ^b   Li, Xiangqian ^a   Song, Ting ^a,c   Wu, Zhiyong ^a   Liang, Xiaomeng ^a   Zhao, Yan ^a   Shen, Xiaoyun ^a   Chen, Hongbo ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b Zhejiang Reachall Pharmaceutial Co Ltd   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Apoptosis; FQ; Fragment based; LE; Mcl 1

Indexed keywords

1 BENZYL 5 (4 ISOPROPYLPHENYLTHIO) 2 OXO 1,2 DIHYDROPYRIDNE 3 CARBONITRILE; 2 CHLORONICOTINIC ACID; 2 CHLORONICOTINOYLCHLORIDE; 2 HYDROXYNICOTINONITRILE; 3 THIOMORPHOLIN 8OXO 8H ACENAPHTHO [1,2 B] PYRROLE 9 CARBONITRILE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 METHOXY 2 HYDROXYNICOTINONITRILE; 5 (4 AMINOPHENYLTHIO) 2 HYDROXYNICOTINONITRILE; 5 (4 BIPHENYL) 2 HYDROXYNICOTINONITRILE; 5 (4 BROMOPHENYLTHIO) 2 HYDROXYNICOTINONITRILE; 5 (4 CHLOROPHENYL) 2 HYDROXYNICOTINONITRILE; 5 (4 ISOPROPYLTHIOPHENOL) 2 HYDROXYNICOTINONITRILE; 5 (4 METHYLTHIOPHENOL) 2 HYDROXYNICOTINONITRILE; 5 (4 TERT AMYLTHIOPHENOL) 2 HYDROXYNICOTINONITRILE; 5 BROMO 2 HYDROXYNICOTINONITRILE; 5 NAPHTHYL 2 HYDROXYNICOTINONITRILE; 5 PHENYL 2 HYDROXYNICOTINONITRILE; 5 PHENYLTHIO 2 HYDROXYNICOTINONITRILE; MCL 1 INHIBITOR; N BENZYL 2 CHLORONICOTINAMIDE; N BENZYL 5 BROMO 2 HYDROXYNICOTINAMIDE; N BUTYL 2 CHLORONICOTINAMIDE; N BUTYL 5 BROMO 2 HYDROXYNICOTINAMIDE; N ISOPROPYL 2 CHLORONICOTINAMIDE; N ISOPROPYL 5 BROMO 2 HYDROXYNICOTINAMIDE; N PHENYLPROPYL 2 CHLORONICOTINAMIDE; NICOTINAMIDE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN MCL 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; LEUKEMIA CELL LINE; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; NIACINAMIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84872167041     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.12.016     Document Type: Article

References (33)

1. J.M. Adams, and S. Cory The Bcl-2 protein family: arbiters of cell survival Science 281 1998 1322 1326
2. D.T. Chao, and S.J. Korsmeyer Bcl-2 family: regulators of cell death Annu. Rev. Immunol. 16 1998 395 419
3. A.J. Minn, R.E. Swain, A. Ma, and C.B. Thompson Recent progress on the regulation of apoptosis by Bcl-2 family members Adv. Immunol. 70 1998 245 279
4. S.N. Willis, and J.M. Adams Life in the balance: how BH3-only proteins induce apoptosis Curr. Opin. Cell. Biol. 17 2005 617 625
5. M.R. Warr, and G.C. Shore Unique biology of Mcl-1: therapeutic opportunities in cancer Curr. Mol. Med. 8 2008 138 147
6. P.H. Bernardo, T. Sivaraman, K.F. Wan, J. Xu, J. Krishnamoorthy, C.M. Song, L. Tian, J.S.F. Chin, D.S.W. Lim, H.Y.K. Mok, V.C. Yu, J.C. Tong, and C.L.L. Chai Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1 J. Med. Chem. 53 2010 2314 2318
7. E.F. Lee, P.E. Czabotar, M.F. van Delft, E.M. Michalak, M.J. Boyle, S.N. Willis, H. Puthalakath, P. Bouillet, P.M. Colman, D.C.S. Huang, and W.D. Fairlie A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation J. Cell. Biol. 180 2008 341 355
8. Z. Zhang, T. Song, T. Zhang, G. Wu, J. Gao, L. An, and G. Du A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1 Int. J. Cancer 128 2011 1724 1735
9. Z. Zhang, G. Wu, F. Xie, T. Song, and X. Chang 3-thiomorpholin-8-oxo-8H- ace-naphtha [1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies J. Med. Chem. 4 2011 1101 1105
10. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
11. A.A. Alex, and M.M. Flocco Fragment-based drug discovery: what has it achieved so far? Curr. Top. Med. Chem. 7 2007 1544 1567
12. M. Congreve, G. Chessari, D. Tisi, and A.J. Woodhead Recent developments in fragment-based drug discovery J. Med. Chem. 51 2008 3661 3680
13. G. Chessari, and A.J. Woodhead From fragment to clinical candidate-a historical perspective Drug Discov. Today 14 2009 668 675
14. M.N. Schulz, and R.E. Hubbard Recent progress in fragment-based lead discovery Curr. Opin. Pharmacol. 9 2009 615 621
15. C.W. Murray, M.G. Carr, O. Callaghan, G. Chessari, M. Congreve, S. Cowan, J.E. Coyle, R. Downham, E. Figueroa, M. Frederickson, B. Graham, and R. McMenamin Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency J. Med. Chem. 53 2010 5942 5955
16. D.A. Erlanson, R.S. McDowell, and T. O'Brien Fragment-based drug discovery J. Med. Chem. 47 2004 3463 3482
17. D.A. Erlanson Fragment-based lead discovery: a chemical update Curr. Opin. Biotechnol. 17 2006 643 652
18. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
19. C. Abad-Zapatero, and J.T. Metz Ligand efficiency indices as guide-posts for drug discovery Drug Discov. Today 10 2005 464 469
20. C.H. Reynolds, S.D. Bembenek, and B.A. Tounge The role of molecular size in ligand efficiency Bioorg. Med. Chem. Lett. 17 2007 4258 4261
21. S.D. Bembenek, B.A. Tounge, and C.H. Reynolds Ligand efficiency and fragment-based drug discovery Drug Discov. Today 14 2009 278 283
22. S. Schultes, C. de Graaf, E.E.J. Haaksma, I.J.P. de Esch, R. Leurs, and O. Kraamer Ligand efficiency as a guide in fragment hit selection and optimization Drug Discov. Today 7 2010 157 161
23. L. Hao, J. Zhou, and Y. Sun studies on the synthesis of gimeracil J. Shengyang Pharm. Univ. 22 2005 420 421
24. R. Church, R. Trust, J.D. Albright, and D.W. Powell New synthetic routes to 3-, 5-, and 6-aryl-2-chloropyridine J. Org. Chem. 60 1995 3750 3758
25. I. Stoll, R. Brodbeck, B. Neumann, H.G. Stammler, and J. Mattay Controlling the self assembly of arene functionalised 2-aminopyrimidines by arene-perfluoroarene interaction and by silver(I) complex formation Cryst. Eng. Commun. 11 2009 306 317
26. L.C. Meurer, P.E. Finke, S.G. Mills, and T.F. Walsh Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists Bioorg. Med. Chem. Lett. 15 2005 645 651
27. B.L. Duell, J.A. Bristo1, R.E. Weishaar, and D.B. Evans 1,2-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds synthesis and inotropic activity J. Med. Chem. 30 1987 1023 1029
28. D. Fattori Molecular recognition: the fragment approach in lead generation Drug Discov. Today 9 2004 229 238
29. C. Yang, and S. Wang Analysis of flexibility and hotspots in Bcl-xL and Mcl-1 proteins for the design of selective small-molecule inhibitors Med. Chem. Lett. 2012 doi:org/10.1021/ml200301w
30. Moore V. Del Gaizo, K.D. Schlis, S.E. Sallan, S.A. Armstrong, and A. Letai Bcl-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia Blood 111 2008 2300 2309
31. K.J. Aichberger, M. Mayerhofer, M.T. Krauth, H. Skvara, S. Florian, K. Sonneck, C. Akgul, S. Derdak, and W.F. Pickl Identification of mcl-1 as a BCR-ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides Blood 105 2004 3303 3311
32. G. Wang, Z. Nikolovska-Coleska, C.Y. Yang, R. Wang, G. Tang, J. Guo, S. Shangary, S. Qiu, W. Gao, D. Yang, J. Meagher, J. Stuckey, K. Krajewski, S. Jiang, P.P. Roller, H.O. Abaan, Y. Tomita, and S. Wang Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins J. Med. Chem. 49 2006 6139 6142
33. Z. Nikolovska-Coleska, R. Wang, X. Fang, H. Pan, Y. Tomita, P. Li, P.P. Roller, K. Krajewski, N.G. Saito, J.A. Stuckey, and S. Wang Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization Anal. Biochem. 332 2004 261 273